These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27401377)

  • 1. [Cost effectiveness of a theoretical cardiac rehabilitation program after myocardial infarction].
    López-Montecinos P; Rebolledo S J; Gómez L JM
    Rev Med Chil; 2016 Apr; 144(4):456-64. PubMed ID: 27401377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and cost-effectiveness of a Yoga-based Cardiac Rehabilitation (Yoga-CaRe) program following acute myocardial infarction: Study rationale and design of a multi-center randomized controlled trial.
    Chandrasekaran AM; Kinra S; Ajay VS; Chattopadhyay K; Singh K; Singh K; Praveen PA; Soni D; Devarajan R; Kondal D; Manchanda SC; Hughes AD; Chaturvedi N; Roberts I; Pocock S; Ebrahim S; Reddy KS; Tandon N; Prabhakaran D;
    Int J Cardiol; 2019 Apr; 280():14-18. PubMed ID: 30661847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Exercise-Based Cardiac Rehabilitation in Chilean Patients Surviving Acute Coronary Syndrome.
    Serón P; Gaete M; Oliveros MJ; Román C; Lanas F; Velásquez M; Reveco R; Bustos L; Rojas R
    J Cardiopulm Rehabil Prev; 2019 May; 39(3):168-174. PubMed ID: 31021998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of comprehensive cardiac telerehabilitation on one-year cardiovascular rehospitalization rate, medical costs and quality of life: A cost-effectiveness analysis.
    Frederix I; Hansen D; Coninx K; Vandervoort P; Vandijck D; Hens N; Van Craenenbroeck E; Van Driessche N; Dendale P
    Eur J Prev Cardiol; 2016 May; 23(7):674-82. PubMed ID: 26289723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
    Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA
    Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Value From Cardiac Rehabilitation: A Cost-Utility Analysis Comparing Age, Sex, and Clinical Subgroups.
    Leggett LE; Hauer T; Martin BJ; Manns B; Aggarwal S; Arena R; Austford LD; Meldrum D; Ghali W; Knudtson ML; Norris CM; Stone JA; Clement F
    Mayo Clin Proc; 2015 Aug; 90(8):1011-20. PubMed ID: 26149321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
    Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Utility Analysis of a Cardiac Telerehabilitation Program: The Teledialog Project.
    Kidholm K; Rasmussen MK; Andreasen JJ; Hansen J; Nielsen G; Spindler H; Dinesen B
    Telemed J E Health; 2016 Jul; 22(7):553-63. PubMed ID: 26713491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cost-effectiveness of providing full coverage for preventive medications after myocardial infarction.
    Ito K; Avorn J; Shrank WH; Toscano M; Spettel C; Brennan T; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):252-9. PubMed ID: 25944633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cardiac rehabilitation program delivery models in patients at varying cardiac risk, reason for referral, and sex.
    Papadakis S; Reid RD; Coyle D; Beaton L; Angus D; Oldridge N
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):347-53. PubMed ID: 18525392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
    Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
    Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
    J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of cardiac rehabilitation after myocardial infarction.
    Ades PA; Pashkow FJ; Nestor JR
    J Cardiopulm Rehabil; 1997; 17(4):222-31. PubMed ID: 9271765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction.
    Lamotte M; Annemans L; Kawalec P; Zoellners Y
    Herz; 2006 Dec; 31 Suppl 3():74-82. PubMed ID: 17575809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G; Solesse A; Beillat M
    Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.